Sulfadiazine Suspension

This product belongs to the sulfonamide broad-spectrum antibacterial drug, which has antibacterial effects on both Gram-positive and Gram-negative bacteria. However, bacterial resistance to this type of drug is common at present. The number of resistant strains in Staphylococcus, gonococci, meningococci, and Enterobacteriaceae has increased. Sulfonamides are also active against the following microorganisms: Chlamydia trachomatis, Nocardia asteroides, Plasmodium falciparum, and Toxoplasma gondii. Sulfonamides are broad-spectrum antibacterial agents, similar in structure to para-aminobenzoic acid (PABA), and can compete with PABA for dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria, reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymidine, and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria. The effects of sulfonamides can be antagonized by PABA and its derivatives (procaine, tetracaine). In addition, the presence of pus and tissue decomposition products also has an antagonistic effect because it provides substances necessary for bacterial growth.

Sulfadiazine

Used for infections such as hemolytic streptococci, meningococci, and pneumococci.

Oral administration, 10 ml at a time, twice a day. For the treatment of meningitis, 10 ml at a time, 4 times a day. Shake well before taking.

1. Allergic reactions are common. It may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and bullous epidermolysis atrophic dermatitis may occur. There are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and occasionally aplastic anemia. Patients may present with sore throat, fever, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after taking sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Neonates have imperfect liver function, so they are more likely to develop hyperbilirubinemia and neonatal jaundice, and occasionally kernicterus. 5. Liver damage. Jaundice and liver dysfunction may occur, and in severe cases, acute liver necrosis may occur. 6. Kidney damage. Crystalluria, hematuria, and tubular urine may occur; occasionally, patients may experience serious adverse reactions such as interstitial nephritis or renal tubular necrosis. 7. Nausea, vomiting, decreased appetite, diarrhea, headache, fatigue, etc. Generally, the symptoms are mild and do not affect continued medication. Occasionally, patients develop Clostridium difficile enteritis, and the drug should be discontinued at this time. 8. Occasionally, thyroid enlargement and hypofunction occur. 9. Central nervous system toxicity may occasionally occur, manifested as mental confusion, disorientation, hallucinations, euphoria or depression, and the drug should be discontinued immediately if it occurs. Although serious adverse reactions caused by sulfonamides are rare, they can be fatal, such as exudative erythema multiforme, exfoliative dermatitis, epidermolysis bullosa atrophic dermatitis, fulminant liver necrosis, agranulocytosis, aplastic anemia and other blood system abnormalities. Patients should be closely observed during treatment, and the drug should be discontinued immediately if a rash or other early signs of a reaction appear. The above adverse reactions are more common in AIDS patients than in non-AIDS patients. The adverse reactions of sulfonamides involve various organs, which may be related to their metabolic process in the body and the patient's condition. The main form of metabolism of sulfonamides in the body is acetylation, but the toxicity of this type of drug is difficult to fully explain by acetylation. Sulfonamides are detoxified by glutathione and other toxic substances that can be cleared by cells under normal conditions. However, some patients, such as those with immunodeficiency, have low glutathione concentrations in their bodies, which leads to the accumulation of metabolites and toxic reactions. There are two types of acetylation processes for sulfonamides in the human body: fast and slow. Allergic reactions are more common in those with slow acetylation.

It is contraindicated for those who are allergic to sulfonamides, newborns and infants under two months old, and those with poor liver and kidney function.

Not yet clear.

Keep in a dark, airtight container in a cool and dry place

10%(g/ml)

Suzhong Pharmaceutical Group Co., Ltd.

• Founded in:

  1979-11-26

• Address:

  No. 1 Suzhong Road, Taizhou City, Jiangsu Province

• Tax NO.:

  91321200141355745E

• Registered Funds:

  160 million yuan

• Website:

  Log in to view

• Email:

  Log in to view